<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Binmama S</submitter><funding>Chulalongkorn University through Fundamental Fund 65</funding><funding>The Program Management Unit for Human Resources &amp;amp; Institutional Development, Research, and Innovation</funding><pagination>10951</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9505986</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>23(18)</volume><pubmed_abstract>Although the impacts of &lt;i>Saccharomyces cerevisiae&lt;/i> on cancers are mentioned, data on its use in mice with cyclic GMP-AMP synthase deficiency (cGAS-/-) are even rarer. Here, 12 weeks of oral administration of &lt;i>S. cerevisiae&lt;/i> protected cGAS-/- mice from azoxymethane (AOM)-induced colon cancers, partly through dysbiosis attenuation (fecal microbiome analysis). In parallel, a daily intralesional injection of a whole glucan particle (WGP; the beta-glucan extracted from &lt;i>S. cerevisiae&lt;/i>) attenuated the growth of subcutaneous tumor using MC38 (murine colon cancer cell line) in cGAS-/- mice. Interestingly, the incubation of fluorescent-stained MC38 with several subtypes of macrophages, including M1 (using Lipopolysaccharide; LPS), M2 (IL-4), and tumor-associated macrophages (TAM; usi</pubmed_abstract><journal>International journal of molecular sciences</journal><pubmed_title>Beta-Glucan from &lt;i>S. cerevisiae&lt;/i> Protected AOM-Induced Colon Cancer in cGAS-Deficient Mice Partly through Dectin-1-Manipulated Macrophage Cell Energy.</pubmed_title><pmcid>PMC9505986</pmcid><funding_grant_id>B16F640175 and B05F640144</funding_grant_id><funding_grant_id>CUFRB65_hea [33] _040_30_21</funding_grant_id><pubmed_authors>Cheibchalard T</pubmed_authors><pubmed_authors>Hiengrach P</pubmed_authors><pubmed_authors>Chindamporn A</pubmed_authors><pubmed_authors>Binmama S</pubmed_authors><pubmed_authors>Pisitkun P</pubmed_authors><pubmed_authors>Visitchanakun P</pubmed_authors><pubmed_authors>Dang CP</pubmed_authors><pubmed_authors>Somboonna N</pubmed_authors><pubmed_authors>Leelahavanichkul A</pubmed_authors></additional><is_claimable>false</is_claimable><name>Beta-Glucan from &lt;i>S. cerevisiae&lt;/i> Protected AOM-Induced Colon Cancer in cGAS-Deficient Mice Partly through Dectin-1-Manipulated Macrophage Cell Energy.</name><description>Although the impacts of &lt;i>Saccharomyces cerevisiae&lt;/i> on cancers are mentioned, data on its use in mice with cyclic GMP-AMP synthase deficiency (cGAS-/-) are even rarer. Here, 12 weeks of oral administration of &lt;i>S. cerevisiae&lt;/i> protected cGAS-/- mice from azoxymethane (AOM)-induced colon cancers, partly through dysbiosis attenuation (fecal microbiome analysis). In parallel, a daily intralesional injection of a whole glucan particle (WGP; the beta-glucan extracted from &lt;i>S. cerevisiae&lt;/i>) attenuated the growth of subcutaneous tumor using MC38 (murine colon cancer cell line) in cGAS-/- mice. Interestingly, the incubation of fluorescent-stained MC38 with several subtypes of macrophages, including M1 (using Lipopolysaccharide; LPS), M2 (IL-4), and tumor-associated macrophages (TAM; usi</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Sep</publication><modification>2025-05-29T20:02:58.243Z</modification><creation>2025-05-29T20:02:58.243Z</creation></dates><accession>S-EPMC9505986</accession><cross_references><pubmed>36142859</pubmed><doi>10.3390/ijms231810951</doi></cross_references></HashMap>